Cryoport, Inc. (CYRX) stock
Close on Nov 12, 2026Market cap $1.02BP/E –Yield –
Cryoport, Inc. grew revenue 11.8% to $192.44M over the twelve months to Sep 30, 2026. Free cash flow was -$18.81M. At the latest close the market valued the company at $1.02B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.02B
- P/E ratio
- –
- Price to sales
- 5.29
- Price to book
- 2.11
- Dividend yield
- –
- Free cash flow yield
- -1.85%
Fundamentals
- Revenue
- $192.44M
- Net income
- -$41.30M
- EPS, diluted
- -$0.97
- Free cash flow
- -$18.81M
- Book value per share
- $9.55
- Diluted shares
- 51M
Trading
- Next earnings
- Mar 2, 2027 (estimated, during market hours)
- Previous close
- $20.56
- Open
- $20.30
- Day's range
- $19.49 – $20.37
- Volume
- 659,180
- Average volume (20 days)
- 1,284,760
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.92
- 52-week range
- $7.61 – $21.78
- RSI (14 days)
- 66.3
- Volatility (1 year)
- 50.7%
- Relative volume
- 1.55×
- WACC
- 14.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CYRX | S&P 500 | Difference | CYRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +19.4% | -2.7% | +22.1 pts | ||
| 3 months | +35.8% | -1.7% | +37.6 pts | ||
| Year to date | +109.4% | +11.9% | +97.5 pts | ||
| 1 year | +127.6% | +12.0% | +115.6 pts | ||
| 3 years | +74.6% | +78.2% | −3.5 pts | +20.4% | +21.2% |
| 5 years | -73.9% | +73.2% | −147.1 pts | -23.5% | +11.6% |
| 10 years | +822.0% | +309.6% | +512.4 pts | +24.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cryoport filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Cryoport
Pharmaceutical Preparations
Cryoport provides temperature-controlled supply chain solutions for the life sciences industry, focusing on cell and gene therapies. The company operates in two segments: Life Sciences Services and Life Sciences Products. Its services include temperature-sensitive logistics, biostorage, sample management, kitting, labeling, and cryopreservation of cell materials. Its products segment designs and manufactures cryogenic equipment, such as freezers and dewars for biological storage and transit. Cryoport serves biopharmaceutical companies, research and academic institutions, laboratories, fertility clinics, animal health businesses, and government agencies.
Company profile, executives and historyCryoport stock: common questions
What is Cryoport's stock price?
CYRX closed at $20.10 on Nov 12, 2026, down 2.24% on the day. Over the past 52 weeks it traded between $7.61 and $21.78.
What is Cryoport's market cap?
Cryoport was worth $1.02B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CYRX's P/E ratio?
Cryoport lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.97), so it has no meaningful P/E ratio.
How much revenue does Cryoport make?
Cryoport reported revenue of $192.44M for the twelve months to Sep 30, 2026, up 11.8% from a year earlier.
Does Cryoport pay a dividend?
No. Cryoport has not paid a cash dividend over the last twelve months.
When does Cryoport report earnings next?
Cryoport is expected to report Q4 FY2026 results on Mar 2, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CYRX stock performed over the past year?
Including dividends, CYRX returned +127.6% over the past year, against +12.0% for the S&P 500.
How many CYRX shares are sold short?
3M shares were sold short at the latest FINRA report, 7.12% of the float, or 4.1 days of average trading volume.
Who are Cryoport's competitors?
Companies most similar to Cryoport by business, industry and size include MRVI, KMDA, LAB, HRTX, LGND.
See a number that looks wrong?